Palbociclib Doubles Survival in Women with Advanced Breast Cancer
the Cancer Therapy Advisor take:
According to a new study published online today in the journal The Lancet Oncology, researchers from Jonsson Comprehensive Cancer Center in Los Angeles, California, have found that palbociclib doubled progression-free survival in women with advanced breast cancer compared with those who did not receive the drug.
For the phase 2 study, researchers enrolled 165 post-menopausal women with advanced estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Patients received letrozole with or without palbociclib.
Results showed that progression-free survival was 20.2 months in the letrozole plus palbociclib arm versus 10.2 months in the letrozole only arm, corresponding with a 51% decreased risk of disease progression with palbociclib.
Furthermore, over 80% of those with metastatic estrogen receptor-positive disease experienced some benefit from the addition of palbociclib. In regard to safety, palbociclib caused leukopenia, but only to a manageable extent. Palbociclib prevents cancer cell proliferation by targeting CDK4/6 proteins, which are responsible for cell growth.
Palbociclib was granted Breakthrough Therapy Designation in 2013 by the U.S. Food and Drug Administration (FDA), and researchers are currently conducting an international phase 3 study in conjunction with Pfizer of palbociclib in 660 estrogen receptor-positive, HER2-negative advanced breast cancer.
Palbociclib doubled PFS in women with ER-positive, HER2-positive advanced breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC
- Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer